患者的普罗波输液综合征风险:来自FAERS数据和已发表的病例报告的见解
Yongyi Zhang1, Mengying Qian1, Aili Zheng1
1School of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong, China.
European journal of pharmacology
|March 3, 2025
概括
患有的患者在使用普罗福尔治疗时,患有普罗福尔输液综合征 (PRIS) 和死亡的风险更高,特别是在使用酸时. 密切监测对于这些患者至关重要.
科学领域:
- 麻醉学和重症监护医学
- 神经学 神经学
- 药物监督 药物监督 药物监督
背景情况:
- 普罗波输液综合征 (PRIS) 是一种罕见但严重的并发症,与使用普罗波有关.
- 在患者中,PRIS的临床特征和风险因素仍然不完全理解.
- 及其用抗药物 (AED) 治疗可能会影响PRIS的发生.
研究的目的:
- 研究,抗药和PRIS之间的关系.
- 阐明PRIS在患者中的临床特征.
- 为了比较和非患者之间的PRIS表现.
主要方法:
- 从FAERS数据库 (2013-2023) 中回顾PRIS案件的分析.
- 根据指示信息区分患者.
- 人口,和AED数据的多变量分析.
- 审查已公布的PRIS报告,其中涉及到propofol.
主要成果:
- 是PRIS (ROR=3.89) 和死亡率 (ROR=1.997) 的重要危险因素.
- 瓦尔酸的使用与PRIS风险增加 (ROR=3.264) 和不良结果 (ROR=2.518) 相关.
- 与非患者相比,患者的普罗波福尔输注率中位数较低,但累计剂量较高.
结论:
- 患者在治疗期间面临PRIS和死亡的高风险.
- 对于接受普罗波的患者来说,警的安全监测至关重要.
- 建议在患者同时使用酸时特别小心.
相关概念视频
Parenteral Anesthetics: Overview
92
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
92
Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140
Antiepileptic Drugs: GABAergic Pathway Potentiators
306
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
306
Arteries of the Lower Limbs
176
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
176
Seizures: Classification
297
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
297
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
209
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
209


